Developer · RVPH · United States

Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings is a clinical-stage pharmaceutical company developing next-generation therapeutics for central nervous system, cardiovascular, metabolic, respiratory, and inflammatory diseases. Its lead candidate is brilaroxazine (RP5063), a serotonin-dopamine signaling modulator in late-stage development for schizophrenia and other neuropsychiatric indications.

revivapharma.com ↗

1compound
1program
1indication
Phase 3lead asset

Phase distribution

  • Phase 31

Modality

  • Small molecule 1

Mechanism focus

Pipeline (1)

Deals & partnerships

  • May 14, 2026Stock listing changeReviva common stock moves from Nasdaq to OTCQBCommon stock began OTCQB quotation at market open 2026-05-14 (ticker RVPH unchanged) following Nasdaq delisting — a capital-constraint signal at the sponsor of a Phase 3 asset, disclosed in the Q1 2026 results PR and the 2026-05-13 8-K (item 3.01).Brilaroxazine (RP5063)source ↗
  • Mar 20, 2026FinancingReviva closes $10M public offering to fund RECOVER-2 Phase 3 of brilaroxazinePriced 2026-03-18 at $1.50/share with Series G (5-yr) and Series H (12-mo) warrants, ~$10M gross via A.G.P.; closed 2026-03-20, leaving ~$23M cash guided into Q1 2027. Proceeds explicitly earmarked for the planned RECOVER-2 Phase 3 trial of brilaroxazine in schizophrenia. Follows a 1:20 reverse split effected 2026-03-09.Brilaroxazine (RP5063)source ↗

Catalysts · 1 upcoming · 3 reported

  • 1H 2027 enrollment start (topline thereafter)Delayed

    Brilaroxazine (RP5063)forSchizophreniaTopline data

    RECOVER-2 confirmatory Phase 3 has not started: enrollment guidance moved mid-2026 -> Q3 2026 -> 1H 2027, subject to additional financing; topline thereafter

    source ↗

Recently reported

Recent activity

  • Dec 23, 2025ReadoutBrilaroxazine (RP5063)·SchizophreniapendingFDA recommends a confirmatory second Phase 3 (RECOVER-2) before a brilaroxazine schizophrenia NDA.source ↗
  • Jun 2, 2025ReadoutBrilaroxazine (RP5063)·SchizophreniametFull 1-year RECOVER open-label extension positive: durable, dose-related efficacy with favorable long-term safety.source ↗
  • Apr 15, 2024Phase changeBrilaroxazine (RP5063)·SchizophreniaPhase 3Reviva reported FDA alignment on the brilaroxazine schizophrenia NDA path: two positive Phase 3 efficacy studies at Week 4 plus >=12 months of long-term safety data could support an NDA for acute treatment of schizophrenia.source ↗
  • Oct 30, 2023ReadoutBrilaroxazine (RP5063)·SchizophreniametPhase 3 RECOVER met its primary endpoint: brilaroxazine 50 mg cut PANSS total by 10.1 points vs placebo at Week 4 (p<0.001).source ↗
  • Jan 24, 2022Phase changeBrilaroxazine (RP5063)·SchizophreniaPhase 3Pivotal Phase 3 RECOVER trial (NCT05184335) started: 28-day randomized, double-blind, placebo-controlled study of brilaroxazine 15 mg and 50 mg vs placebo in acute schizophrenia, followed by a 52-week open-label extension.source ↗

Competitive landscape

Other companies developing against Reviva Pharmaceuticals Holdings, Inc.'s targets or indications.

Leadership & advisors (6)